NCT05975931View on ClinicalTrials.gov

IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.

TerminatedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Epilepsy
Trial Locations (1)

Unknown

Queen Elizabeth Hospital Birmingham, Birmingham

Sponsors

Lead Sponsor

LivaNova
All Listed Sponsors
collaborator

OPEN VIE Limited

UNKNOWN

lead

LivaNova

INDUSTRY

NCT05975931 - IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes. | Biotech Hunter | Biotech Hunter